Abstract:The very high energy demand of the heart is primarily met by ATP production from mitochondrial oxidative phosphorylation, with glycolysis providing a smaller amount of ATP production. This ATP production is markedly altered in heart failure, primarily due to a decrease in mitochondrial oxidative metabolism. Although an increase in glycolytic ATP production partly compensates for the decrease in mitochondrial ATP production, the failing heart faces an energy deficit, that contributes to the severity of contractile dysfunction. The relative contribution of the different fuels for mitochondrial ATP production dramatically changes in the failing heart, which depends to a large extent on the type of heart failure. A common metabolic defect in all forms of heart failure (including HFrEF, HFpEF, and diabetic cardiomyopathies) is a decrease in mitochondrial oxidation of pyruvate originating from glucose (i.e. glucose oxidation). This decrease in glucose oxidation occurs regardless of whether glycolysis is increased, resulting in an uncoupling of glycolysis from glucose oxidation that can decrease cardiac efficiency. The mitochondrial oxidation of fatty acids by the heart increases or decreases, depending on the type of heart failure. For instance, in HFpEF and diabetic cardiomyopathies myocardial fatty acid oxidation increases, while in HFrEF myocardial fatty acid oxidation either decreases or remains unchanged. The oxidation of ketones (which provides the failing heart with an important energy source) also differs depending on the type of heart failure, being increased in HFrEF, and decreased in HFpEF and diabetic cardiomyopathies. The alterations in mitochondrial oxidative metabolism and glycolysis in the failing heart are due to transcriptional changes in key enzymes involved in the metabolic pathways, as well as alterations in redox state, metabolic signaling, and posttranslational epigenetic changes in energy metabolic enzymes. Of importance, targeting the mitochondrial energy metabolic pathways has emerged as a novel therapeutic approach to improving cardiac function and cardiac efficiency in the failing heart.

Mitochondrial Calcium Overload Plays a Causal Role in Oxidative Stress in the Failing Heart

Mitochondria-associated membrane-modulated Ca<SUP>2+</SUP> transfer: A potential treatment target in cardiac ischemia reperfusion injury and heart failure

A Mitochondrial Basis for Heart Failure Progression

Mitochondrial Ca2+ regulation in the etiology of heart failure: physiological and pathophysiological implications

From Pathophysiological Mechanisms to Therapeutic Opportunities

Mitochondrial calcium regulation of cardiac metabolism in health and disease

Mitochondrial Dysfunction in Heart Failure and Its Therapeutic Implications

Mitochondrial dysfunction and mitochondrial therapies in heart failure

The Role of Mitochondrial Fusion and Fission in the Process of Cardiac Oxidative Stress.

Novel insights into the involvement of mitochondrial fission/fusion in heart failure: From molecular mechanisms to targeted therapies

Mitochondrial autophagy: molecular mechanisms and implications for cardiovascular disease

Improving effect of physical exercise on heart failure: Reducing oxidative stress-induced inflammation by restoring Ca2+ homeostasis

Mitochondrial Ca2+ Homeostasis: Emerging Roles and Clinical Significance in Cardiac Remodeling

Mitochondrial dynamics and cell death in heart failure

NADPH Oxidase and Cardiac Failure

Mechanical stress induced mitochondrial dysfunction in cardiovascular diseases: Novel mechanisms and therapeutic targets

Immunity, Inflammation, and Oxidative Stress in Heart Failure: Emerging Molecular Targets

Posttranslational modifications and dysfunction of mitochondrial enzymes in human heart failure

Mitochondrial Stress as a Central Player in the Pathogenesis of Hypoxia-Related Myocardial Dysfunction: New Insights

Advances in myocardial energy metabolism: metabolic remodeling in heart failure and beyond

Alterations in Mitochondrial Oxidative Phosphorylation System: Relationship of Complex V and Cardiac Dysfunction in Human Heart Failure